SCHEMBL31662295

SCHEMBL31662295

Nc1nc(OC[C@@]23CCCN2C[C@H](F)C3)nc2c(F)c(Cl)nc(OC3CC3)c12

nearest known ligand 0.49

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
KRAS P01116 20/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30229810 0.80 KRAS (0.57) KRAS
SCHEMBL26598245 0.80 KRAS (0.47) KRAS
SCHEMBL26598179 0.78 KRAS (0.44) KRAS
SCHEMBL30887768 0.78 KRAS (0.45) KRAS
SCHEMBL26598263 0.78 KRAS (0.45) KRAS
SCHEMBL31348395 0.78 KRAS (0.44) KRAS
SCHEMBL27117610 0.77 KRAS (0.48) KRAS
SCHEMBL30832235 0.76 MAPK3 (0.52) KRAS
SCHEMBL31214595 0.76 KRAS (0.48) KRAS
SCHEMBL30702840 0.76 KRAS (0.49) KRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151594-A1 FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS INC. (US) 2025-07-17 WO disclosed